Search
Evorpacept
go.drugbank.com/drugs/DB17573InvestigationalEvorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
Ethaselen
go.drugbank.com/drugs/DB15051InvestigationalEthaselen is under investigation in clinical trial NCT02166242 (Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers).
Mizolastine
go.drugbank.com/drugs/DB12523ApprovedMizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).
Categories: Antihistamines for Systemic UseIclaprim
go.drugbank.com/drugs/DB06358InvestigationalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTesmilifene
go.drugbank.com/drugs/DB04905InvestigationalTesmilifene is a novel potentiator of chemotherapy which, when added to doxorubicin, achieved an unexpected and very large survival advantage over doxorubicin alone in a randomized trial in advanced breast cancer.
Imidocarb
go.drugbank.com/drugs/DB11521ExperimentalVet approvedImidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.
Etiracetam
go.drugbank.com/drugs/DB11868ExperimentalEtiracetam is under investigation in clinical trial NCT01137110 (Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)).
Ribaxamase
go.drugbank.com/drugs/DB16311InvestigationalRibaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).
OTX-2002
go.drugbank.com/drugs/DB17246InvestigationalOTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).
BNT111
go.drugbank.com/drugs/DB18177InvestigationalBNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.